Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)

NCT00661492 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

115

Enrollment

INDUSTRY

Sponsor class

Conditions

Androgen-independent Prostate Cancer

Interventions

DRUG: cetuximab
DRUG: Mitoxantrone

Sponsor

US Oncology Research

Collaborators

[object Object]
[object Object]